Project Grant R01DK142415
Award Date 8/20/26
Completion Date 5/31/30
Dollars Obligated $940K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
La Jolla, CA 92037, USA
Similar Awards
- The National Institute of Diabetes and Digestive and Kidney Diseases, part of the Department of Health and Human Services National Institutes of Health, awarded Baylor College of Medicine $167,165 on July 2, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate molecular mechanisms of T cell dysfunction in pediatric chronic cholestatic liver diseases. The research program, spanning five years through March 31, 2031, and performed in...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Mayo Clinic $670,268 on August 15, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate cholangiocyte-driven proinflammatory signaling in primary sclerosing cholangitis (PSC). The research employs spatial analysis of human PSC liver tissues and murine disease models to define how cholangiocytes engage the innate immune system via neutrophil recruitment and...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Mayo Clinic $671,966 on August 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate cholangiocyte pathobiology in primary sclerosing cholangitis. The research addresses PSC pathogenesis and therapeutic targets through examination of cholangiocyte senescence and a proposed viral mimicry mechanism. The project tests the hypothesis that PSC cholangiocytes...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Yale University $802,715 on March 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate pathogen-induced biliary inflammation in sclerosing cholangiopathies, particularly primary sclerosing cholangitis (PSC). The research examines how biliary epithelial cells respond to gut-derived pathobionts, pathogen-associated molecular patterns, and pro-inflammatory...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Regents of the University of California, San Francisco $626,188 on May 15, 2026, to develop a therapy for human cholestatic liver diseases based on hepatocyte plasticity. The research aims to investigate how hepatocyte plasticity—the ability of liver cells to assume a biliary identity and form functional bile ducts—can be harnessed therapeutically in diseases including Alagille Syndrome and primary sclerosing...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the University of Pittsburgh $550,070 on August 15, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct research elucidating ATP8B1 deficiency using patient-derived induced pluripotent stem cell (iPSC) models. The project addresses progressive familial intrahepatic cholestasis (PFIC) caused by ATP8B1 mutations, a rare inherited liver disease that impairs bile...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the University of Texas Health Science Center at Houston $154,332 on March 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate the role of kynurenine-aryl hydrocarbon receptor signaling in cholestatic liver injury. The research examines how the kynurenine pathway and aryl hydrocarbon receptor activation regulate reactive oxygen species accumulation,...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Virginia Commonwealth University $352,242 on September 15, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate the role of the transcription factor RUNX1 in cholangiocyte signaling and biliary fibrosis. The project will examine how RUNX1 coordinates transcriptomic and lipidomic programs in cholangiocytes activated by transforming growth factor-beta, with...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the University of Texas Health Science Center at Houston $158,220 on May 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate the role of neutrophil-derived HIF1A signaling in hepatic ischemia/reperfusion injury. The research addresses mechanisms of graft dysfunction following liver transplantation, a leading cause of poor outcomes in end-stage liver...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Icahn School of Medicine at Mount Sinai $155,832 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate matrix metalloproteinase-7 (MMP7)–expressing hepatic stellate cells as drivers of fibrosis progression in biliary atresia. The funded project will define the transcriptomic and spatial identity of MMP7+ hepatic stellate cells in biliary atresia...